GF Fund Management CO. LTD. Takes Position in argenx SE (NASDAQ:ARGX)

GF Fund Management CO. LTD. bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 677 shares of the company's stock, valued at approximately $416,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARGX. FMR LLC boosted its stake in argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of argenx during the 4th quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC increased its holdings in shares of argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock valued at $89,391,000 after purchasing an additional 143,834 shares in the last quarter. Marshall Wace LLP grew its stake in argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after acquiring an additional 124,271 shares during the period. Finally, Capital World Investors grew its stake in argenx by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after acquiring an additional 86,687 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several recent research reports. Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenx in a research report on Friday, April 11th. Oppenheimer boosted their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a research note on Tuesday, May 13th. Wells Fargo & Company boosted their price objective on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Citigroup reissued a "buy" rating on shares of argenx in a research report on Wednesday, May 21st. One analyst has rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $709.18.

argenx Stock Performance

NASDAQ:ARGX traded down $9.68 during trading hours on Friday, hitting $571.28. The company's stock had a trading volume of 154,582 shares, compared to its average volume of 322,919. The business's 50-day moving average is $587.15 and its two-hundred day moving average is $612.54. The company has a market capitalization of $34.88 billion, a PE ratio of -650.64 and a beta of 0.57. argenx SE has a 52-week low of $359.37 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.